EVLO
Income statement / Annual
Last year (2022), Evelo Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Evelo Biosciences, Inc.'s net income was -$114.53 M.
See Evelo Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$78.55 M
|
$83.64 M
|
$69.62 M
|
$63.13 M
|
$39.89 M
|
$19.96 M
|
$9.13 M
|
| General & Administrative Expenses |
$29.91 M
|
$31.75 M
|
$22.27 M
|
$23.23 M
|
$18.22 M
|
$7.57 M
|
$3.89 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$29.91 M
|
$31.75 M
|
$22.27 M
|
$23.23 M
|
$18.22 M
|
$7.57 M
|
$3.89 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$20.00 K
|
| Operating Expenses |
$108.47 M
|
$115.40 M
|
$91.89 M
|
$86.36 M
|
$58.10 M
|
$27.53 M
|
$13.03 M
|
| Cost And Expenses |
$108.47 M
|
$115.40 M
|
$91.89 M
|
$86.36 M
|
$58.10 M
|
$27.53 M
|
$13.03 M
|
| Interest Income |
$4.67 K
|
$3.61 K
|
$0.00
|
$1.05 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$4.67 M
|
$3.61 M
|
$2.11 M
|
$1.05 M
|
$1.56 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.06 M
|
$2.22 M
|
$2.03 M
|
$1.76 K
|
$1.94 K
|
$834.00
|
$495.00
|
| EBITDA |
-$106.35 M |
-$115.40 M |
-$89.86 M |
-$84.42 M |
-$58.10 M |
-$26.70 M |
-$12.53 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$5.13 M
|
-$6.35 M
|
-$1.37 M
|
$885.00 K
|
$1.16 M
|
-$516.00 K
|
-$307.00 K
|
| Income Before Tax |
-$113.60 M
|
-$121.75 M
|
-$93.26 M
|
-$85.47 M
|
-$56.95 M
|
-$28.05 M
|
-$13.33 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$930.00 K
|
$428.00 K
|
$409.00 K
|
$190.00 K
|
-$3.09 M
|
$215.00 K
|
$0.00
|
| Net Income |
-$114.53 M
|
-$122.18 M
|
-$93.67 M
|
-$85.66 M
|
-$53.85 M
|
-$28.05 M
|
-$13.33 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-26.28 |
-46.18 |
-47.45 |
-53.49 |
-49.25 |
-149.98 |
-94.55 |
| EPS Diluted |
-26.28 |
-46.18 |
-47.45 |
-53.49 |
-49.25 |
-149.55 |
-94.06 |
| Weighted Average Shares Out |
$4.36 M
|
$2.65 M
|
$1.97 M
|
$1.60 M
|
$1.09 M
|
$187.00 K
|
$141.00 K
|
| Weighted Average Shares Out Diluted |
$4.36 M
|
$2.65 M
|
$1.97 M
|
$1.60 M
|
$1.09 M
|
$187.54 K
|
$141.74 K
|
| Link |
|
|
|
|
|
|
|
